Ocular Therapeutix financials
$7.87+2.81%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $52.0M | $63.7M | $58.4M | $51.5M | $43.5M | $17.4M | $4.2M | $2.0M | $1.9M | $1.9M |
| Gross profit | $45.4M | $58.1M | $53.2M | $47.0M | $39.1M | $15.3M | $1.9M | $1.5M | $1.5M | $1.4M |
| Gross margin | 87.3% | 91.2% | 91.0% | 91.2% | 89.9% | 88.0% | 45.0% | 76.6% | 76.2% | 76.5% |
| Operating income | -$270.0M | -$171.8M | -$82.4M | -$78.7M | -$78.0M | -$62.8M | -$85.8M | -$59.1M | -$61.9M | -$43.3M |
| Net income | -$265.9M | -$193.5M | -$80.7M | -$71.0M | -$6.6M | -$155.6M | -$86.4M | -$60.0M | -$63.4M | -$44.7M |
| Net margin | −511.9% | −303.7% | −138.1% | −138.0% | −15.1% | −894.3% | −2043.3% | −3014.0% | −3296.2% | −2369.0% |
| Diluted EPS | $-1.42 | $-1.22 | $-1.02 | $-0.97 | $-0.98 | $-2.56 | $-1.91 | $-1.57 | $-2.20 | $-1.80 |
| EBITDA | -$265.7M | -$168.0M | -$79.4M | -$76.5M | -$75.6M | -$60.1M | -$83.3M | -$56.8M | -$60.3M | -$42.4M |
| Operating cash flow | -$204.9M | -$134.7M | -$70.2M | -$59.6M | -$65.5M | -$53.6M | -$77.6M | -$49.2M | -$50.5M | -$34.0M |
| Free cash flow | -$216.9M | -$136.0M | -$76.3M | -$63.3M | -$66.7M | -$54.4M | -$79.8M | -$51.1M | -$58.7M | -$35.9M |
| Diluted shares | 187.2M | 158.3M | 85.6M | 82.6M | 82.2M | 60.8M | 45.3M | 38.1M | 28.8M | 24.8M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $737.1M | $392.1M | $195.8M | $102.3M | $164.2M | $228.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $71.3M | $68.5M | $74.9M | $54.0M | $51.4M | $49.5M |
| Total assets | $808.1M | $457.9M | $252.1M | $149.3M | $204.9M | $261.9M |
| Total liabilities | $153.7M | $142.6M | $160.9M | $113.9M | $116.9M | $185.8M |
| Shareholders' equity | $654.3M | $315.3M | $91.1M | $35.4M | $88.0M | $76.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology